People · Operator

K.A. AJIT-SIMH

Named in public records as an officer, director or promoter · active 2009–2010 · Biotechnology

1
Companies
2
Filings
$187.3M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Arena Pharmaceuticals IncBiotechnologySeries D+$187.3M$1.5B2009
Operator network

K.A. AJIT-SIMH at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Tina S. Nova · 3 companies · 1 sharedTina S. NovaChristine A. White · 2 companies · 1 sharedChristine A. WhiteRandall E. Woods · 2 companies · 1 sharedRandall E. WoodsRobert E. Hoffman · 2 companies · 1 sharedRobert E. HoffmanDOMINIC P. BEHAN · 1 companies · 1 sharedDOMINIC P. BEHANDONALD D. BELCHER · 1 companies · 1 sharedDONALD D. BELCHERHARRY F. HIXSON, JR. · 1 companies · 1 sharedHARRY F. HIXSON, …JACK LIEF · 1 companies · 1 sharedJACK LIEFJ. CLAYBURN LA FORCE, JR. · 1 companies · 1 sharedJ. CLAYBURN LA FO…PHILLIP M. SCHNEIDER · 1 companies · 1 sharedPHILLIP M. SCHNEI…SCOTT H. BICE · 1 companies · 1 sharedSCOTT H. BICESTEVEN W. SPECTOR · 1 companies · 1 sharedSTEVEN W. SPECTORWILLIAM R. SHANAHAN, JR. · 1 companies · 1 sharedWILLIAM R. SHANAH…Arena Pharmaceuticals Inc · $187.3M raisedArena Pharmaceuticals…K.A. AJIT-SIMHKA
K.A. AJIT-SIMH Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside K.A. AJIT-SIMH on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Tina S. Nova13
Randall E. Woods12
Robert E. Hoffman12
Christine A. White12
HARRY F. HIXSON, JR.11
DOMINIC P. BEHAN11
J. CLAYBURN LA FORCE, JR.11
SCOTT H. BICE11
WILLIAM R. SHANAHAN, JR.11
PHILLIP M. SCHNEIDER11
DONALD D. BELCHER11
STEVEN W. SPECTOR11
JACK LIEF11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.